CN1541203A - 4-(苯基-(哌啶-4基)-氨基)-苯甲酰胺衍生物及其在治疗疼痛、焦虑症或胃肠病中的应用 - Google Patents

4-(苯基-(哌啶-4基)-氨基)-苯甲酰胺衍生物及其在治疗疼痛、焦虑症或胃肠病中的应用 Download PDF

Info

Publication number
CN1541203A
CN1541203A CNA028141733A CN02814173A CN1541203A CN 1541203 A CN1541203 A CN 1541203A CN A028141733 A CNA028141733 A CN A028141733A CN 02814173 A CN02814173 A CN 02814173A CN 1541203 A CN1541203 A CN 1541203A
Authority
CN
China
Prior art keywords
compound
phenyl
piperidin
benzyl
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA028141733A
Other languages
English (en)
Chinese (zh)
Inventor
W
W·布朗
A·格里芬
C·瓦尔波尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of CN1541203A publication Critical patent/CN1541203A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
CNA028141733A 2001-05-18 2002-05-16 4-(苯基-(哌啶-4基)-氨基)-苯甲酰胺衍生物及其在治疗疼痛、焦虑症或胃肠病中的应用 Pending CN1541203A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE01017714 2001-05-18
SE0101771A SE0101771D0 (sv) 2001-05-18 2001-05-18 Novel compounds

Publications (1)

Publication Number Publication Date
CN1541203A true CN1541203A (zh) 2004-10-27

Family

ID=20284174

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA028141733A Pending CN1541203A (zh) 2001-05-18 2002-05-16 4-(苯基-(哌啶-4基)-氨基)-苯甲酰胺衍生物及其在治疗疼痛、焦虑症或胃肠病中的应用

Country Status (23)

Country Link
US (1) US7186733B2 (cg-RX-API-DMAC7.html)
EP (1) EP1395556A1 (cg-RX-API-DMAC7.html)
JP (1) JP2005508290A (cg-RX-API-DMAC7.html)
KR (1) KR20040000470A (cg-RX-API-DMAC7.html)
CN (1) CN1541203A (cg-RX-API-DMAC7.html)
AR (1) AR033760A1 (cg-RX-API-DMAC7.html)
BG (1) BG108332A (cg-RX-API-DMAC7.html)
BR (1) BR0209675A (cg-RX-API-DMAC7.html)
CA (1) CA2446316A1 (cg-RX-API-DMAC7.html)
CO (1) CO5540318A2 (cg-RX-API-DMAC7.html)
CZ (1) CZ20033091A3 (cg-RX-API-DMAC7.html)
EE (1) EE200300535A (cg-RX-API-DMAC7.html)
HU (1) HUP0401324A2 (cg-RX-API-DMAC7.html)
IL (1) IL158630A0 (cg-RX-API-DMAC7.html)
IS (1) IS7029A (cg-RX-API-DMAC7.html)
MX (1) MXPA03010442A (cg-RX-API-DMAC7.html)
NO (1) NO20035114D0 (cg-RX-API-DMAC7.html)
PL (1) PL366770A1 (cg-RX-API-DMAC7.html)
RU (1) RU2003131965A (cg-RX-API-DMAC7.html)
SE (1) SE0101771D0 (cg-RX-API-DMAC7.html)
SK (1) SK13972003A3 (cg-RX-API-DMAC7.html)
WO (1) WO2002094784A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200308641B (cg-RX-API-DMAC7.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103724366A (zh) * 2014-01-21 2014-04-16 贵州威顿晶磷电子材料有限公司 一种对羧基苯硼酸的制备方法
CN107531670A (zh) * 2014-12-19 2018-01-02 菲勒诺沃公司 二芳基亚甲基哌啶衍生物及其作为δ阿片受体激动剂的用途

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE425152T1 (de) * 2002-03-13 2009-03-15 Janssen Pharmaceutica Nv Aminocarbonylderivate als histone-deacetylase- inhibitoren
SE0300987D0 (sv) * 2003-04-03 2003-04-03 Astrazeneca Ab Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof
NZ593444A (en) 2003-10-01 2012-12-21 Adolor Corp 4-[(2-N,N-diethylaminocarbonyl)pyrid-5-yl]-spiro[1,2-dihydronaphthalene-2,4'-piperidine] and methods of its use
US7598261B2 (en) 2005-03-31 2009-10-06 Adolor Corporation Spirocyclic heterocyclic derivatives and methods of their use
US7576207B2 (en) 2006-04-06 2009-08-18 Adolor Corporation Spirocyclic heterocyclic derivatives and methods of their use
EP4333821A4 (en) * 2021-05-04 2025-07-09 Texas A & M Univ Sys SARS-COV-2 INHIBITORS

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4091096A (en) 1976-03-19 1978-05-23 Eli Lilly And Company Dinitroanilines for the control of phytopathogens
EG12406A (en) 1976-08-12 1979-03-31 Janssen Pharmaceutica Nv Process for preparing of novel n-aryl-n-(1-l-4-piperidinyl)-arylacetamides
SE441448B (sv) 1977-05-23 1985-10-07 Pfizer Sett att framstella hexahydro-gamma-karbolinforeningar
US4252812A (en) 1977-05-23 1981-02-24 Pfizer Inc. 2-Substituted-trans-5-aryl-2,3,4,4a,5,9b-hexahydro-1H-pyrido[4,3-b]indoles
DE3200304A1 (de) 1981-01-16 1982-08-26 Sandoz-Patent-GmbH, 7850 Lörrach 3-aminopropoxyaryl-derivate, ihre herstellung und sie enthaltende arzneimittel
EP0181793B1 (fr) 1984-10-16 1988-07-27 Synthelabo Dérivés de pipéridine, leur préparation et leur application en thérapeutique
US5188693A (en) * 1986-04-18 1993-02-23 Aishin Kakou K.K. Process for applying polyvinyl chloride sealing material having low thixotropic index
KR940003491B1 (ko) 1989-08-10 1994-04-23 리히터 게데온 베기에스제티 기아르 알.티 4,4-이중 치환된 피페리딘 유도체와 그 제조방법 및 상기 화합물을 함유하는 약제학적 조성물
YU150489A (sh) 1989-08-10 1992-12-21 W.L. Gore & Co. Gmbh. Uređaj za ispitivanje odevnih predmeta na nepromočivost
US5854245A (en) 1996-06-28 1998-12-29 Merck & Co., Inc. Fibrinogen receptor antagonists
TW548271B (en) * 1996-12-20 2003-08-21 Astra Pharma Inc Novel piperidine derivatives having an exocyclic double bond with analgesic effects
SE9604786D0 (sv) * 1996-12-20 1996-12-20 Astra Pharma Inc New compounds
ZA9811842B (en) 1997-12-24 2000-06-23 Ortho Mcneil Pharm Inc 4-[aryl(piperidin-4-yl)]aminobenzamides.
EP1061919A4 (en) 1998-03-10 2002-09-04 Res Triangle Inst NOVEL OPIOUS COMPOUNDS AND PROCESSES FOR THEIR PREPARATION AND USE
SE9904675D0 (sv) * 1999-12-20 1999-12-20 Astra Pharma Inc Novel compounds
EP1263758A2 (en) * 2000-03-03 2002-12-11 Ortho-McNeil Pharmaceutical, Inc. 3-(diarylmethylene)-8-azabicyclo[3.2.1]octane derivatives
US6556387B1 (en) * 2000-03-31 2003-04-29 Seagate Technology Llc Controlling mechanical response characteristics of a disc drive actuator by adjusting a fastener engaging the actuator shaft to vary axial force on the bearing assembly
SE0001207D0 (sv) * 2000-04-04 2000-04-04 Astrazeneca Canada Inc Novel compounds

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103724366A (zh) * 2014-01-21 2014-04-16 贵州威顿晶磷电子材料有限公司 一种对羧基苯硼酸的制备方法
CN103724366B (zh) * 2014-01-21 2016-04-27 贵州威顿晶磷电子材料股份有限公司 一种对羧基苯硼酸的制备方法
CN107531670A (zh) * 2014-12-19 2018-01-02 菲勒诺沃公司 二芳基亚甲基哌啶衍生物及其作为δ阿片受体激动剂的用途
CN107531670B (zh) * 2014-12-19 2020-12-15 菲勒诺沃公司 二芳基亚甲基哌啶衍生物及其作为δ阿片受体激动剂的用途

Also Published As

Publication number Publication date
NO20035114D0 (no) 2003-11-17
JP2005508290A (ja) 2005-03-31
KR20040000470A (ko) 2004-01-03
BR0209675A (pt) 2004-07-27
HUP0401324A2 (hu) 2004-11-29
US7186733B2 (en) 2007-03-06
CA2446316A1 (en) 2002-11-28
ZA200308641B (en) 2005-02-07
SE0101771D0 (sv) 2001-05-18
EE200300535A (et) 2004-02-16
RU2003131965A (ru) 2005-05-10
AR033760A1 (es) 2004-01-07
CZ20033091A3 (cs) 2004-07-14
IL158630A0 (en) 2004-05-12
CO5540318A2 (es) 2005-07-29
PL366770A1 (en) 2005-02-07
BG108332A (bg) 2004-12-30
EP1395556A1 (en) 2004-03-10
SK13972003A3 (en) 2004-10-05
MXPA03010442A (es) 2004-03-09
IS7029A (is) 2003-11-12
WO2002094784A1 (en) 2002-11-28
US20040142965A1 (en) 2004-07-22

Similar Documents

Publication Publication Date Title
CN1269805C (zh) 4－(苯基－哌嗪基－甲基)－苯甲酰胺衍生物及其在治疗疼痛、焦虑症或胃肠病中的应用
CN1185228C (zh) 治疗疼痛的羟苯基－亚哌啶－4－基－甲基－苯甲酰胺衍生物
CN1261098C (zh) p38－α激酶的抑制剂
CN1671672A (zh) 芳基取代的苯并咪唑类及其作为钠通道阻滞剂的用途
JP2001522800A (ja) ベンゾチアゾールたんぱくチロシン・キナーゼ抑制剤
CN1816332A (zh) 3－氨基甲基－吡咯烷作为n－型钙通道阻断剂
CN1816524A (zh) 用于神经退行性疾病的治疗的选择性五羟色胺2a/2c受体反向激动剂
CN1636980A (zh) 二肽腈组织蛋白酶k抑制剂
CN1124960A (zh) 作为5-ht/a和/或5-ht2配体的吲哚衍生物
CN1509282A (zh) 4-(苯基-哌啶-4-基亚基-甲基)-苯甲酰胺衍生物及其在治疗疼痛、焦虑或胃肠疾病中的用途
CN1360502A (zh) 多巴胺d3受体配体在生产肾功能紊乱治疗药物中的应用
CN1692100A (zh) 4－[哌啶－4－亚基－(3－氨基甲酰苯基)甲基]苯甲酰胺衍生物及其在治疗疼痛、脊椎损伤或胃肠疾病方面的应用
CN1182134C (zh) 用于治疗疼痛的喹啉基-亚哌啶-4-基-甲基-苯甲酰胺衍生物
CN1541203A (zh) 4-(苯基-(哌啶-4基)-氨基)-苯甲酰胺衍生物及其在治疗疼痛、焦虑症或胃肠病中的应用
CN1225465C (zh) 新化合物
CN1509271A (zh) 4-(苯基-哌啶-4-基亚基-甲基)-苯甲酰胺衍生物及其在治疗疼痛、焦虑或胃肠疾病中的用途
CN1608064A (zh) 新化合物
CN1527828A (zh) 4-(苯基-哌啶-4-基亚基-甲基)-苯甲酰胺衍生物及其在治疗疼痛、焦虑或胃肠疾病中的用途
CN1711251A (zh) 4－(苯基－哌嗪基－甲基)苯甲酰胺衍生物及其在治疗疼痛或胃肠疾病中的用途
CN1422266A (zh) 用于治疗疼痛的羟苯基－哌嗪基－甲基－苯甲酰胺衍生物
CN1639123A (zh) 4－(苯基－(哌啶－4－基)－氨基)－苯甲酰胺衍生物及其在治疗疼痛、焦虑症或胃肠道疾病中的应用
CN1993338A (zh) 二芳基甲基哌嗪衍生物及其制备方法和用途
CN1012364B (zh) 治疗老年精神病的环酰胺和酰亚胺的二氮杂苯基哌啶衍生物的制备方法
CN1620435A (zh) 4－(苯基－(哌啶－4－基)－氨基)－苯甲酰胺衍生物及其在治疗疼痛、焦虑症或胃肠病中的应用
CN1547579A (zh) 4-(苯基-哌啶-4-基亚基-甲基)-苯甲酰胺衍生物及其在治疗疼痛、焦虑或胃肠疾病中的用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication